This company has been marked as potentially delisted and may not be actively trading. NASDAQ:HSGX Histogenics (HSGX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Histogenics Stock (NASDAQ:HSGX) 30 days 90 days 365 days Advanced Chart Get Histogenics alerts:Sign Up Key Stats Today's Range$0.93▼$0.9750-Day Range$0.16▼$3.0752-Week Range$0.08▼$1.43Volume2.12 million shsAverage Volume9.06 million shsMarket Capitalization$90.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts. Read More Receive HSGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Histogenics and its competitors with MarketBeat's FREE daily newsletter. Email Address HSGX Stock News HeadlinesTraphaco JSC TRAJuly 31, 2024 | morningstar.comMFeargal Sharkey: Desperate revival of failed policies doesn’t add upApril 7, 2023 | thetimes.co.ukTWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.August 7 at 2:00 AM | InvestorPlace (Ad)Aspect Biosystems Appoints Three New Board Members - StreetInsider.comSeptember 21, 2022 | streetinsider.comAspect Biosystems Appoints Three New Board Members - Business WireSeptember 21, 2022 | businesswire.comAre Ocugen Or Amarin Good Stocks To Buy? - Investing.comAugust 24, 2022 | investing.com2022-08-05 | NDAQ:OCGN | Press Release | Ocugen, Inc. - StockhouseAugust 5, 2022 | stockhouse.comOcugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition - GuruFocus.comJune 23, 2022 | gurufocus.comSee More Headlines HSGX Stock Analysis - Frequently Asked Questions How were Histogenics' earnings last quarter? Histogenics Corp (NASDAQ:HSGX) announced its earnings results on Thursday, August, 9th. The biotechnology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.10. When did Histogenics IPO? Histogenics (HSGX) raised $60 million in an IPO on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager. What other stocks do shareholders of Histogenics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Histogenics investors own include Interpace Biosciences (IDXG), Verastem (VSTM), Progenics Pharmaceuticals (PGNX), Novavax (NVAX), SCYNEXIS (SCYX), Ocular Therapeutix (OCUL) and OPKO Health (OPK). Company Calendar Last Earnings8/09/2018Today8/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical Appliances & Supplies Sub-IndustryN/A Current SymbolNASDAQ:HSGX CIK1372299 Webwww.histogenics.com Phone781-547-7900FaxN/AEmployees49Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.64 million Net MarginsN/A Pretax MarginN/A Return on Equity-34.96% Return on Assets18.40% Debt Debt-to-Equity RatioN/A Current Ratio4.05 Quick Ratio4.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-95.83Miscellaneous Outstanding Shares94,599,000Free FloatN/AMarket Cap$90.65 million OptionableNot Optionable Beta3.10 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:HSGX) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Histogenics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Histogenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
